Editas Medicine, Inc.

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies